CNVCF
BioHarvest Sciences Inc.·Healthcare
6.30
0.000%(+0.00)
Market ClosedLast Updated: — ET
52W L: $6.3052W H: $6.30
BioHarvest Sciences Inc.·Healthcare
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) has reported its financial results for the fourth quarter and full year 2025, highlighting revenue growth, improved margins, and continued investment in its product and contract manufacturing businesses. The company recorded full-year revenue of $34.5 million, representing a 37% increase compared to 2024.
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) announced that it has completed the first stage of a multi-phase development program focused on a rare scent-producing plant used in the global fragrance industry. The work was carried out through the company's contract development and manufacturing organization (CDMO) division under an agreement signed about a year ago.
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said its VINIA product has become the top-selling resveratrol polyphenol nutraceutical brand in the United States, citing company data, as it continues to expand its direct-to-consumer business. The biotechnology company attributed VINIA's market position to its clinically studied ability to support arterial dilation and blood flow, a mechanism it says can enhance oxygen and nutrient delivery throughout the body.
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Thursday that it has appointed former Israeli health ministry chief Hezi Levy to the board effective immediately. David Tsur will step down from its board of directors after more than four years of service, the company said in a statement.